Biotech company Efferon has secured €2.5 million in seed funding to advance its fight against sepsis and septic shock. The investment, led by private investors from the DACH region, will fuel the European expansion of its innovative blood purification technology. This follows the company's recent milestone of receiving CE MDR certification for its pediatric hemoadsorption device, Efferon NEO.
A Novel Approach to Blood Purification
Efferon has developed a hemoadsorption platform to treat life-threatening conditions by removing harmful substances directly from the bloodstream. Its devices filter out endotoxins and inflammatory mediators, which are key drivers of systemic inflammation in critical illnesses. This intervention aims to restore balance to the body's immune response and help prevent organ failure.
The company's portfolio includes Efferon LPS for adults and the newly certified Efferon NEO for pediatric and neonatal patients. According to Efferon, its technology can reduce ICU costs by enabling faster stabilization of patients in septic shock. This leads to less time on mechanical ventilation and shorter stays in intensive care, improving patient outcomes.
Strategic Funding to Scale Operations
The new €2.5 million in capital provides a crucial boost for Efferon's growth strategy across Europe. The funding will be instrumental in expanding the rollout of its flagship device, Efferon LPS, making the therapy more accessible. This financial injection underscores investor confidence in the company's technology and its potential to transform critical care.
A primary allocation for the investment is the construction of a new production facility within the European Union. This new site will significantly increase the company's manufacturing capacity for its hemoadsorption cartridges. The expansion is a direct response to the growing global demand for its blood purification therapies for sepsis.
Landmark Approval for Pediatric Sepsis Care
Efferon recently achieved a major regulatory milestone with the CE MDR certification for Efferon NEO. This approval marks it as the first hemoadsorption device in Europe specifically cleared for use in neonatal and pediatric patients with sepsis. The certification opens a new frontier in treating the most vulnerable patient populations with advanced technology.
The approval was supported by positive clinical results from the multicentre LASSO NEO study, which validated the device's efficacy. Dima Romashin, CEO of Efferon, noted this gives clinicians a purpose-built device for children, addressing a critical gap. He emphasized the mission to ensure the standard of care for children is as advanced as for adults.
Global Impact and Future Ambitions
Efferon's technology is already making a significant impact globally, having been used in more than 25,000 treatments. The devices are deployed in over 40 countries, including major markets like Germany, the United Kingdom, and Australia. This widespread adoption demonstrates the therapy's established clinical utility and growing international recognition.
Looking ahead, the company envisions applications for its hemoadsorption platform beyond the intensive care unit. Systemic inflammation is a factor in numerous chronic and age-related diseases, presenting a vast field for future innovation. This perspective suggests a long-term strategy to leverage its core technology across a broader spectrum of medical conditions.
With fresh capital and a groundbreaking pediatric device certification, Efferon is strongly positioned to enhance its market presence and manufacturing capabilities. The company's dual focus on expanding its adult solutions and pioneering pediatric care addresses a critical global health challenge. This advancement reinforces its mission to place sepsis at the forefront of the medical agenda and improve patient outcomes.